Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul;103(4):613-628.
doi: 10.1016/j.mcna.2019.02.007.

Premenstrual Dysphoric Disorder

Affiliations
Review

Premenstrual Dysphoric Disorder

Teresa Lanza di Scalea et al. Med Clin North Am. .

Abstract

Premenstrual dysphoric disorder (PMDD) comprises emotional and physical symptoms and functional impairment that lie on the severe end of the continuum of premenstrual symptoms. Women with PMDD have a differential response to normal hormonal fluctuations. This susceptibility may involve the serotonin system, altered sensitivity of the GABAA receptor to the neurosteroid allopregnanalone, and altered brain circuitry involving emotional and cognitive functions. Serotonin reuptake inhibitors are considered the first-line treatment. Second-line treatments include oral contraceptives containing drospirenone, other ovulation suppression methods, calcium, chasteberry, and cognitive-behavioral therapy.

Keywords: Antidepressant; Etiology; Oral contraceptive; Premenstrual dysphoric disorder; Premenstrual syndrome; Treatment.

Similar articles

See all similar articles

Cited by 2 articles

MeSH terms

Substances

Feedback